Metamizol Noridem

Metamizole Sodium Monohydrate, the active ingredient in Metamizol Noridem, is a pyrazolone (non‑opioid analgesic) presented as a sterile injectable solution for intramuscular or intravenous use. It is employed to treat pain, fever, and post‑operative discomfort in adult patients.

GNH USA supplies Metamizol Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Metamizole is used in the management of acute pain and fever, acting within the analgesic and antipyretic therapeutic classes.

- Pain: provides rapid relief of moderate to severe acute pain. - Fever: reduces elevated body temperature in febrile states. - Post‑operative pain: controls pain following surgical procedures.

Metamizole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Dizziness: transient light‑headedness. - Hypotension: occasional drop in blood pressure after rapid injection. - Injection site pain: local discomfort at the administration site.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Severe allergic reactions (anaphylaxis): rapid onset of systemic hypersensitivity. - Stevens‑Johnson syndrome: serious skin and mucous membrane disorder.

Before prescribing Metamizole, clinicians should consider several safety measures.

- Assess patient history: check for prior hypersensitivity to pyrazolones. - Monitor blood counts: especially during prolonged therapy. - Avoid use in patients with known bone marrow disorders. - Use with caution in renal or hepatic impairment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metamizole can interact with other medicines; awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive agents: increased risk of agranulocytosis. - Combination with other NSAIDs: heightened gastrointestinal toxicity. - Co‑administration with drugs that affect platelet function: increased bleeding risk.

Moderate Interactions (Monitor Closely): - Interaction with anticoagulants: may potentiate anticoagulant effect. - Use with antihypertensives: possible additive hypotensive effect. - Concurrent use with drugs metabolized by CYP enzymes: potential altered plasma levels.